En español
NIDA

Drugged Driving

NIDA Cosponsors International Symposium on Drugged Driving at EMCDDA

NIDA International Program Director Steven W. Gust, Ph.D., co-chaired the Third International Symposium on Drug-Impaired Driving, which was held in Lisbon, Portugal, on October 23, 2017. The prevalence of drug-impaired driving has begun to rival that of alcohol-impaired driving in some parts of the world, resulting in a greater focus on the ability to detect drug-impaired drivers using roadside screening tools and efforts to establish “per se” limits for drug use.

ICADTS Conference Session Explores Role of New Psychoactive Drugs

The 2013 International Council on Alcohol, Drugs and Traffic Safety (ICADTS) conference featured a session on the impact of new psychoactive drugs on traffic safety. NIDA International Program Director Steven W. Gust, Ph.D., and Marilyn A. Huestis, Ph.D., NIDA Intramural Research Program, co-chaired the session and described the rapid emergence of these designer drugs. By mid-2013, more than 90 nations had reported that new psychoactive substances were available in their countries, with the 351 new drugs far exceeding the 234 substances controlled under international treaties.

DRUID Conference Focuses on Drugged Driving

The European Union’s (EU) Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) held its last meeting earlier this fall, marking a 5-year effort to gain insight into the full impact of substance abuse on road safety.

EU Study Documents Prevalence of Drugged Driving

A summary report has been issued on the European Union (EU) research project on Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID). The summary reviews the findings of 50 reports, conducted over 5 years across 18 countries, that provide scientific evidence on levels of drug and alcohol use among drivers and recommends actions to improve road safety and policy. Random roadside surveys detected alcohol in 3.5% of drivers; illicit drugs in 1.9% of drivers; and psychoactive medications in 1.4% of drivers.